Gaku Tsuji
Overview
Explore the profile of Gaku Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
1953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maehara E, Kido-Nakahara M, Fujita Y, Kato K, Kido S, Yamasaki R, et al.
Allergy
. 2025 Jan;
PMID: 39812143
No abstract available.
2.
Kawaguchi K, Tsuji G, Kuba-Fuyuno Y, Ichiki T, Imajima M, Kuma Y, et al.
J Dermatol
. 2025 Jan;
PMID: 39797586
No abstract available.
3.
Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S
J Dermatol
. 2024 Dec;
52(2):247-255.
PMID: 39676466
Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) in Japanese patients aged ≥12 years. We evaluated the efficacy and safety of...
4.
Yamamura K, Ohno F, Yotsumoto S, Sato Y, Kimura N, Nishio K, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596359
Atopic dermatitis (AD) is characterized by chronic inflammation, barrier dysfunction, and pruritus, exacerbated by external stimuli, such as scratching. This study investigates the role of extracellular adenosine triphosphate (ATP) in...
5.
Kido-Nakahara M, Chiba T, Mizusawa Y, Higashi Y, Ibusuki A, Igawa S, et al.
Allergol Int
. 2024 Sep;
PMID: 39332980
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with intense pruritus. Dupilumab, an anti-IL-4 receptor alpha antibody, has been revealed to be highly effective against the symptoms of...
6.
Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S
J Dermatol
. 2024 Sep;
51(11):1404-1413.
PMID: 39269202
Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream 1% in Japanese patients aged ≥12 years with atopic dermatitis (AD) in...
7.
Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, et al.
J Allergy Clin Immunol Glob
. 2024 Sep;
3(4):100317.
PMID: 39253106
Background: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti-IL-4Rα antibody, have been developed in...
8.
Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S
J Dermatol
. 2024 Aug;
51(10):1269-1278.
PMID: 39150292
Tapinarof is a non-steroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream (1%) in Japanese patients aged ≥18 years with plaque psoriasis in two...
9.
Tsuji G, Yumine A, Kawamura K, Takemura M, Kido-Nakahara M, Yamamura K, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063153
Difamilast, a phosphodiesterase 4 (PDE4) inhibitor, has been shown to be effective in the treatment of atopic dermatitis (AD), although the mechanism involved remains unclear. Since IL-33 plays an important...
10.
Tsuji G, Yumine A, Kawamura K, Takemura M, Nakahara T
Antioxidants (Basel)
. 2024 Jun;
13(6).
PMID: 38929171
Semaphorin 3A (SEMA3A), a nerve-repellent factor produced by keratinocytes, has an inhibitory effect on nerve extension to the epidermis. Epidermal innervation is involved in pruritus in inflammatory skin diseases such...